For the quarter ending 2025-11-30, CNBX had -$7,408 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-11-30 | 2025-08-31 |
|---|---|---|
| Net loss | -113,719 | -313,976 |
| Depreciation | 0 | 0 |
| Interest on loans | 46,296 | - |
| Share based payment | 0 | 0 |
| Interest on convertible loan | - | -39,813 |
| Capital loss (gain) | - | 0 |
| Decrease (increase) accounts receivable and prepaid expenses | 133 | -1,641 |
| Increase (decrease) accounts payable and accrued liabilities | 20,148 | 101,217 |
| Net cash used in operating activities | -47,408 | -171,305 |
| Sale of equipment | - | 0 |
| Acquisition of equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from the issuance of a short term loan | 40,000 | - |
| Proceeds from the issuance of a convertible loan | 0 | 160,000 |
| Net cash provided by financing activities | 40,000 | 160,000 |
| Net increase (decrease) in cash | -7,408 | -11,305 |
| Cash and cash equivalents at beginning of period | 15,111 | 26,416 |
| Cash and cash equivalents at end of period | 7,703 | 15,111 |
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)